Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
332
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
stocks
ASX listed share dominates their industry
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,288.10 | 53.60 | 0.58% |
CAC 40 | 8,081.54 | 24.91 | 0.31% |
DAX 40 | 24,378.80 | 43.76 | -0.18% |
Dow JONES (US) | 46,758.28 | 238.56 | 0.51% |
FTSE 100 | 9,491.25 | 63.52 | 0.67% |
HKSE | 27,140.92 | 146.20 | -0.54% |
NASDAQ | 22,780.51 | 63.54 | -0.28% |
Nikkei 225 | 45,769.50 | 832.77 | 1.85% |
NZX 50 Index | 13,514.09 | 62.33 | 0.46% |
S&P 500 | 6,715.79 | 0.44 | 0.01% |
S&P/ASX 200 | 8,987.40 | 50.80 | 0.57% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |